Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms 2Lymphoma 2Glioma 2Brain Neoplasms 2Leukemia, Lymphoid 1Disease Progression 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × enzastaurin × Clear all
NCT00108056 2019-12-05

Enzastaurin to Treat Recurrent Brain Tumor

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
26 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Disease Progression

NCT01445119 2013-08-28

A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas

Eli Lilly and Company

Phase 1 Completed
58 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡